Hi Sanfran.
The zen3694 trials are not double blind and therefore can be reported whenever signiificant data is collected and analysed. We are a year into the trial since the first dosing. There may not be a sufficient amount of data to report anything.
However, what is going on in my mind (speculation) is that if they were really getting strong results they would not be so silent unless security against competitors is a factor as has been suggested. I doubt this because they are very open at scientific conferences.
On the positive side;
- The trial is still continuing so they must see some hope.
- As I understand it the first patient dosed on just zen3694 is still alive after a year(???) and that seems positive because I understand it mCRPC is very severe and the trial patients are very ill. I guess this does not mean much because others may have died with no measured effect.
- The first phase must have been positive enough so that they are now moving to the enzalutimide phase.
- They have discovered the most effective dosing...which is a critical step.
Perhaps the data is fuzzy. Still, it doesn't explain why they do not have one of the science or medical people give us a "here is where we are at" presentation in layman's language.
I doubt that they are in discussions with an acquisitor because it is too early...unless, of course, they are seeing outstanding results.
Keep up your great posts.
GLTA
Toinv
